EuroPCR 2022 | GLOBAL SYMPLICITY Registry

The GLOBAL SYMPLICITY Registry is the largest study, with the longest followup, of real-world patients (real world data) presenting high blood pressure, treated with renal denervation. 

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

Time in Target Range (TTR), estimates the time a patient needs to control their blood pressure, and is an independent predictor of cardiovascular events. 

The aim of this registry, open, multicenter, and observational, was to assess the impact of improved TTR after radiofrequency renal denervation on cardiovascular outcomes, and estimate cardiovascular reduction associated to improved blood pressure control. 

3077 consecutive uncontrolled hypertensive patients, treated with the Symplicity™ (Flex o Spyral) radiofrequency renal denervation system, were included and followed up to 3 years. Cutoff values for TTR were office <140 mmHg and 24-hour ambulatory blood pressures <130 mmHg.

Mean age was 60±12 years, office BP was 166 mmHg ±25 and ambulatory BP was 154±19 mmHg; patients were treated with 4.9±1.7 antihypertensive medication classes. Office blood pressure saw a reduction vs. baseline of -13.2 at 6 months, -14 at one year, -15.3 at two years and -16.7 at 3 years (P<0.001). This progressive benefit was also seen in the ambulatory branch, with reduced hypertension values regardless the number of antihypertensives (p=0.007).

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

TTR significantly and progressively increased at followup: 28.2% at 3 months vs. 34.9% at 3 years. As regards safety outcomes, there was a small number of events: creatinine elevation >50% in 1.3%, chronic kidney disease, advance stage, in 1.9% and the presence of new renal stenosis (>70%) in 0.3% of cases.

When looking at MACE, patients with TTR >50% presented fewer events compared against TTR 0-50% (2.9% vs 6.2%; P<0.0001). 10% TTR increase was associated to 16% MACE reduction. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Mahfoud, F. en EuroPCR 2022, París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...